The Life Sciences team advised Kymab on its agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics.
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders.
The cross jurisdictional Goodwin team was led by David Mardle, Liz Rhodes and Malcolm Bates.
For more details, read the press release and articles in Financial Times, Bloomberg, and Reuters.